1. Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome
- Author
-
Tjerk S.J. Opstal, Aernoud T.L. Fiolet, Amber van Broekhoven, Arend Mosterd, John W. Eikelboom, Stefan M. Nidorf, Peter L. Thompson, Michiel Duyvendak, J.W. Martijn van Eck, Eugène A. van Beek, Frank den Hartog, Charley A. Budgeon, Willem A. Bax, Jan G.P. Tijssen, Saloua El Messaoudi, Jan H. Cornel, S.M. Nidorf, X.F. Xu, M.A. Ireland, D. Latchem, A. Whelan, R. Hendriks, P. Salkani, I.W. Tan, A.G. Thompson, A.M. Morton, B.E. Hockings, P.L. Thompson, B. King, J.H. Cornel, H. Bakker-Lohmeijer, A. Mosterd, P. Bunschoten, S.H.K. The, S. van der Kooi, T. Lenderink, R.G.J.L. Lardinois, P.A.M. Hoogslag, A. de Vos, A. Jerzewski, S. Jansen, P.R. Nierop, M. van der Knaap, H.P. Swart, R. Kingma, J. Schaap, L.B. Blom, A.F.M. Kuijper, E. Bayraktar-Verver, M.W.J. van Hessen, W.C.T.C. Engelen, J.W.M. van Eck, N. van der Ven-Elzebroek, J.M.C. van Hal, I.M.J. Drost, F.R. den Hartog, D. van Wijk, E. van Beek, C. van der Horst, G.L. Bartels, M. Hendriks, C. de Nooijer, C. Welten, E. Ronner, A. Dijkshoorn, F.J. Prins, R.N.A. Rutten, D.P.W. Beele, I. Hendriks, A. van der Sluis, E.A. Badings, I.C.D. Westendorp, A. Melein, Tj.J. Römer, P. Bruines, R. van de Wal, I. Leenders - van Lieshout, M.E.W. Hemels, K. Meinen-Werner, M.R. de Groot, G. Post, M.W.C. Mulder, S. Stuij, E. van Nes, P. Luyten, J. Plomp, S.V. Veldmeijer, M.J. Asselman, P.A. Scholtus, Cardiology, ACS - Heart failure & arrhythmias, Human genetics, AMS - Rehabilitation & Development, Plastic, Reconstructive and Hand Surgery, ACS - Atherosclerosis & ischemic syndromes, AMS - Musculoskeletal Health, and ACS - Diabetes & metabolism
- Subjects
Male ,medicine.medical_specialty ,Acute coronary syndrome ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,Infarction ,Coronary disease ,Risk Assessment ,anti-inflammatory agents ,Gout Suppressants ,Time-to-Treatment ,chemistry.chemical_compound ,All institutes and research themes of the Radboud University Medical Center ,Double-Blind Method ,ischemic risk ,Internal medicine ,Outcome Assessment, Health Care ,Humans ,Medicine ,Colchicine ,In patient ,Myocardial infarction ,Acute Coronary Syndrome ,Secondary prevention ,Dose-Response Relationship, Drug ,business.industry ,Incidence ,Middle Aged ,medicine.disease ,Stroke ,myocardial infarction ,chemistry ,cardiovascular inflammation ,Cardiology ,Female ,Drug Monitoring ,atherosclerosis ,Cardiology and Cardiovascular Medicine ,business ,secondary prevention - Abstract
Background: Colchicine reduces risk of cardiovascular events in patients post–myocardial infarction and in patients with chronic coronary disease. It remains unclear whether this effect is related to the time of onset of treatment following an acute coronary syndrome (ACS). Objectives: This study investigates risk for major adverse cardiovascular events in relation to history and timing of prior ACS, to determine whether the benefits of colchicine are consistent independent of prior ACS status. Methods: The LoDoCo2 (Low-Dose Colchicine 2) trial randomly allocated patients with chronic coronary disease to colchicine 0.5 mg once daily or placebo. The rate of the composite of cardiovascular death, spontaneous myocardial infarction, ischemic stroke, or ischemia-driven coronary revascularization was compared between patients with no prior, recent (6-24 months), remote (2-7 years), or very remote (>7 years) ACS; interaction between ACS status and colchicine treatment effect was assessed. Results: In 5,522 randomized patients, risk of the primary endpoint was independent of prior ACS status. Colchicine consistently reduced the primary endpoint in patients with no prior ACS (incidence: 2.8 vs 3.4 events per 100 person-years; hazard ratio [HR]: 0.81; 95% confidence interval [CI]: 0.52-1.27), recent ACS (incidence: 2.4 vs 3.3 events per 100 person-years; HR: 0.75; 95% CI: 0.51-1.10), remote ACS (incidence: 1.8 vs 3.2 events per 100 person-years, HR: 0.55; 95% CI: 0.37-0.82), and very remote ACS (incidence: 3.0 vs 4.3 events per 100 person-years, HR: 0.70; 95% CI: 0.51-0.96) (P for interaction = 0.59). Conclusions: The benefits of colchicine are consistent irrespective of history and timing of prior ACS. (The LoDoCo2 Trial: Low Dose Colchicine for secondary prevention of cardiovascular disease [LoDoCo2] ACTRN12614000093684)
- Published
- 2021
- Full Text
- View/download PDF